JP2003502361A - 安定なキシロメタゾリン及びオキシメタゾリン溶液 - Google Patents

安定なキシロメタゾリン及びオキシメタゾリン溶液

Info

Publication number
JP2003502361A
JP2003502361A JP2001504362A JP2001504362A JP2003502361A JP 2003502361 A JP2003502361 A JP 2003502361A JP 2001504362 A JP2001504362 A JP 2001504362A JP 2001504362 A JP2001504362 A JP 2001504362A JP 2003502361 A JP2003502361 A JP 2003502361A
Authority
JP
Japan
Prior art keywords
formulation according
weight
formulation
solution
xylometazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001504362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003502361A5 (enExample
Inventor
フリーダー ウルリッヒ メルツ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23322017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003502361(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2003502361A publication Critical patent/JP2003502361A/ja
Publication of JP2003502361A5 publication Critical patent/JP2003502361A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Cosmetics (AREA)
JP2001504362A 1999-06-22 2000-06-17 安定なキシロメタゾリン及びオキシメタゾリン溶液 Pending JP2003502361A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33778999A 1999-06-22 1999-06-22
US09/337,789 1999-06-22
PCT/EP2000/005583 WO2000078297A2 (de) 1999-06-22 2000-06-17 Stabile xylometazolin- und oxymetazolinlösung

Publications (2)

Publication Number Publication Date
JP2003502361A true JP2003502361A (ja) 2003-01-21
JP2003502361A5 JP2003502361A5 (enExample) 2007-08-09

Family

ID=23322017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001504362A Pending JP2003502361A (ja) 1999-06-22 2000-06-17 安定なキシロメタゾリン及びオキシメタゾリン溶液

Country Status (22)

Country Link
US (2) US20040191177A1 (enExample)
EP (1) EP1194145B1 (enExample)
JP (1) JP2003502361A (enExample)
KR (1) KR20020012001A (enExample)
CN (1) CN1164271C (enExample)
AT (1) ATE232099T1 (enExample)
AU (1) AU765736B2 (enExample)
BR (1) BR0011950A (enExample)
CA (1) CA2376121C (enExample)
CZ (1) CZ295595B6 (enExample)
DE (1) DE50001217D1 (enExample)
EA (1) EA003329B1 (enExample)
ES (1) ES2188563T3 (enExample)
HK (1) HK1045945B (enExample)
HU (1) HUP0201700A3 (enExample)
IL (1) IL147023A0 (enExample)
MX (1) MXPA01012912A (enExample)
PL (1) PL197542B1 (enExample)
PT (1) PT1194145E (enExample)
TR (1) TR200103694T2 (enExample)
WO (1) WO2000078297A2 (enExample)
ZA (1) ZA200110386B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501817A (ja) * 2003-08-13 2007-02-01 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング オキシメタゾリン及び／又はキシロメタゾリンを含有する医薬水溶液

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1446119B1 (en) * 2001-09-18 2006-03-01 Nycomed Danmark ApS Compositions comprising ipatropium and xylometazoline for treatment of the common cold
CA2489528A1 (en) * 2002-06-20 2003-12-31 Novartis Consumer Health S.A. Nasal compositions comprising a mucopolysaccharide and propylene glycol
WO2004024187A2 (en) * 2002-09-13 2004-03-25 Zicam, Llc. Compositions to reduce congestion and methods for application thereof to the nasal membrane
US20090136598A1 (en) * 2006-04-26 2009-05-28 Aciex, Inc. Compositions for the Treatment and Prevention of Eyelid Swelling
EP2015733A2 (en) * 2006-04-26 2009-01-21 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
CN107249566A (zh) 2014-12-24 2017-10-13 加德兰-盖林斯基实验室有限责任公司 一种以海水作为赋形剂提高稳定性的鼻用组合物
WO2023046590A1 (en) 2021-09-22 2023-03-30 Jadran - Galenski Laboratorij D.D. An improved pharmaceutical composition for nasal use, preparation, and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114979A (en) * 1989-10-18 1992-05-19 Schering Corporation Fruity flavored nasal decongestant composition
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
WO1997018902A1 (de) * 1995-11-17 1997-05-29 Ursatec Verpackung-Gmbh Vor kontamination schützende abgabevorrichtung für fluide
JP2002501884A (ja) * 1998-01-30 2002-01-22 ノバルテイス・コンシユーマー・ヘルス・エス・アー 点鼻用液剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603131A (en) * 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose
US4970240A (en) * 1989-10-18 1990-11-13 Schering Corporation Fruity flavored nasal decongestant composition
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
ES2190477T3 (es) * 1995-11-17 2003-08-01 Ursatec Verpackung Gmbh Dispensador de fluidos diseñado para proteger el contenido de la contaminacion.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114979A (en) * 1989-10-18 1992-05-19 Schering Corporation Fruity flavored nasal decongestant composition
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
WO1997018902A1 (de) * 1995-11-17 1997-05-29 Ursatec Verpackung-Gmbh Vor kontamination schützende abgabevorrichtung für fluide
JP2002501884A (ja) * 1998-01-30 2002-01-22 ノバルテイス・コンシユーマー・ヘルス・エス・アー 点鼻用液剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501817A (ja) * 2003-08-13 2007-02-01 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング オキシメタゾリン及び／又はキシロメタゾリンを含有する医薬水溶液
JP4750703B2 (ja) * 2003-08-13 2011-08-17 マリア クレメンティーネ マルティン クロスターフラウ フェアトリーブスゲゼルシャフト ミット ベシュレンクテル ハフツング オキシメタゾリン及び／又はキシロメタゾリンを含有する医薬水溶液

Also Published As

Publication number Publication date
PT1194145E (pt) 2003-06-30
BR0011950A (pt) 2002-03-12
EA200200042A1 (ru) 2002-06-27
HUP0201700A2 (hu) 2002-12-28
AU6150600A (en) 2001-01-09
EA003329B1 (ru) 2003-04-24
TR200103694T2 (tr) 2002-04-22
MXPA01012912A (es) 2002-09-18
ES2188563T3 (es) 2003-07-01
HUP0201700A3 (en) 2003-02-28
ZA200110386B (en) 2003-04-22
IL147023A0 (en) 2002-08-14
CN1164271C (zh) 2004-09-01
ATE232099T1 (de) 2003-02-15
WO2000078297A2 (de) 2000-12-28
WO2000078297A3 (de) 2001-03-01
AU765736B2 (en) 2003-09-25
US20040191177A1 (en) 2004-09-30
CA2376121A1 (en) 2000-12-28
CA2376121C (en) 2008-06-10
PL352354A1 (en) 2003-08-11
CZ295595B6 (cs) 2005-08-17
KR20020012001A (ko) 2002-02-09
CN1361689A (zh) 2002-07-31
EP1194145A2 (de) 2002-04-10
CZ20014568A3 (cs) 2002-03-13
PL197542B1 (pl) 2008-04-30
HK1045945A1 (en) 2002-12-20
US20080011293A1 (en) 2008-01-17
DE50001217D1 (de) 2003-03-13
EP1194145B1 (de) 2003-02-05
HK1045945B (zh) 2005-01-28

Similar Documents

Publication Publication Date Title
Robinson et al. An timy colic Properties of Thiabendazole.
US20180271836A1 (en) Topical non-aqueous pharmaceutical formulations containing an alkyl sulfoxide for the treatment of topical reference infections
US20130177632A1 (en) 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US20080011293A1 (en) Stable Xylometazoline and Oxymetazoline Solution
JP2581707B2 (ja) 抗真菌剤組成物
US11331289B2 (en) Antimicrobial composition
JP7594260B2 (ja) プロトテカ症の新規治療剤
JP2000516928A (ja) 抗真菌性化合物とｎ―アルキル複素環式化合物とを併用する真菌感染の治療
US4792552A (en) Water-soluble adduct of norfloxacin
JP4970931B2 (ja) 抗菌作用を有し、ジアミンをベースとするグアニジン誘導体
US20080312304A1 (en) Topical compositions containing metronidazole
CN108605976B (zh) 一种用于抑制和杀灭病菌的抗菌剂
US7183315B2 (en) Silver salts of sucrose-octasulphate
RU2436570C1 (ru) Способ лечения эндометритов бактериально-микозной этиологии у коров
US12110310B2 (en) Amphiphilic kanamycin compositions and methods
RU2748748C1 (ru) Противотуберкулёзное средство на основе (Z)-3-(3,3-Диметил-2-оксобутилиден)-3,4-дигидро-2H-1,4-бензоксазин-2-она и способ его синтеза
IL32324A (en) Phenazine derivatives and their preparation
RU2726982C1 (ru) Местное применение диоксидина при инфекционно-воспалительных поражениях эпителия
JPS645596B2 (enExample)
CN103724262B (zh) 一种氟喹诺酮银化合物及其制备方法和用途
JP3777010B2 (ja) 新規ペプチド及びそのペプチドを有効成分とする薬剤
WO2020209215A1 (ja) 抗真菌剤
CN113994971A (zh) 激酶抑制剂在防治农业病原细菌中的用途
RU2563985C2 (ru) Фармацевтическая композиция, содержащая тосуфлоксацин или его соль
JPH0140809B2 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110407